Anika Therapeutics, Inc. (ANIK)
After hours:
| Previous Close | 27.59 |
| Open | 27.91 |
| Bid | 27.44 x 100 |
| Ask | 27.79 x 100 |
| Day's Range | 27.53 - 28.19 |
| 52 Week Range | 16.54 - 28.19 |
| Volume | |
| Avg. Volume | 79,135 |
| Market Cap | 409.118M |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.64 |
| Earnings Date | May 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.33 |
GlobeNewswireAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that on May 1, 2024, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $26.49, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive
Simply Wall St.Anika Therapeutics (NASDAQ:ANIK) shareholders have endured a 37% loss from investing in the stock three years ago
Many investors define successful investing as beating the market average over the long term. But the risk of stock...
- GlobeNewswire
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-888-886-7786 (
